Search research articles
Contact Us
Filters
Showing results (301-310 of 319) with videos related to
Page
of 32
Sort By:
Journal of Crohn'S & Colitis
|
June 13, 2025
Gaps between European Crohn's Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey
Gionata Fiorino, Alissa Walsh, Michel Adamina, et al.
American Journal of Respiratory and Critical Care Medicine
|
October 29, 2015
rAAV-CFTRΔR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis Mice
Dragana Vidović, Marianne S Carlon, Mélanie F da Cunha, et al.
The Lancet. Gastroenterology & Hepatology
|
July 30, 2018
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
Brian G Feagan, Julián Panés, Marc Ferrante, et al.
United European Gastroenterology Journal
|
October 25, 2021
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study
Laurent Goessens, Jean-Frédéric Colombel, An Outtier, et al.
Gastroenterology
|
February 5, 2022
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results
Geert R D'Haens, William J Sandborn, Edward V Loftus, et al.
The New England Journal of Medicine
|
July 17, 2024
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease
Laurent Peyrin-Biroulet, J Casey Chapman, Jean-Frederic Colombel, et al.
Cell Reports
|
April 3, 2013
ER stress causes rapid loss of intestinal epithelial stemness through activation of the unfolded protein response
Jarom Heijmans, Jooske F van Lidth de Jeude, Bon-Kyoung Koo, et al.
Alimentary Pharmacology & Therapeutics
|
November 7, 2019
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study
Annick Moens, C Janneke van der Woude, Mette Julsgaard, et al.
JAMA
|
July 22, 2024
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials
Edouard Louis, Stefan Schreiber, Remo Panaccione, et al.
Gastroenterology
|
March 1, 2022
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results
Julián Panés, Jean-Frederic Colombel, Geert R D'Haens, et al.
Page
of 32
Search research articles
Search
Showing results (301-310 of 319) with videos related to
Sort By:
Page
of 32
Journal of Crohn'S & Colitis
|
June 13, 2025
Gaps between European Crohn's Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey
Gionata Fiorino, Alissa Walsh, Michel Adamina, et al.
American Journal of Respiratory and Critical Care Medicine
|
October 29, 2015
rAAV-CFTRΔR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis Mice
Dragana Vidović, Marianne S Carlon, Mélanie F da Cunha, et al.
The Lancet. Gastroenterology & Hepatology
|
July 30, 2018
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
Brian G Feagan, Julián Panés, Marc Ferrante, et al.
United European Gastroenterology Journal
|
October 25, 2021
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study
Laurent Goessens, Jean-Frédéric Colombel, An Outtier, et al.
Gastroenterology
|
February 5, 2022
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results
Geert R D'Haens, William J Sandborn, Edward V Loftus, et al.
The New England Journal of Medicine
|
July 17, 2024
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease
Laurent Peyrin-Biroulet, J Casey Chapman, Jean-Frederic Colombel, et al.
Cell Reports
|
April 3, 2013
ER stress causes rapid loss of intestinal epithelial stemness through activation of the unfolded protein response
Jarom Heijmans, Jooske F van Lidth de Jeude, Bon-Kyoung Koo, et al.
Alimentary Pharmacology & Therapeutics
|
November 7, 2019
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study
Annick Moens, C Janneke van der Woude, Mette Julsgaard, et al.
JAMA
|
July 22, 2024
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials
Edouard Louis, Stefan Schreiber, Remo Panaccione, et al.
Gastroenterology
|
March 1, 2022
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results
Julián Panés, Jean-Frederic Colombel, Geert R D'Haens, et al.
Page
of 32